Advertisement

A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study

  • Mitsukuni SuenagaEmail author
  • Takeru Wakatsuki
  • Tetsuo Mashima
  • Mariko Ogura
  • Takashi Ichimura
  • Eiji Shinozaki
  • Izuma Nakayama
  • Hiroki Osumi
  • Yumiko Ota
  • Daisuke Takahari
  • Keisho Chin
  • Hiroyuki Seimiya
  • Kensei Yamaguchi
PHASE I STUDIES
  • 478 Downloads

Summary

Background The effectiveness of reintroducing oxaliplatin for metastatic colorectal cancer (mCRC) refractory to both oxaliplatin and irinotecan was previously reported in a phase II study (RE-OPEN). We conducted a phase I study to determine the maximum tolerated dose of oxaliplatin plus trifluridine/tipiracil (FTD/TPI) in patients with refractory mCRC. Patients and Methods Three dosages of intravenous oxaliplatin (50, 65 and 85 mg/m2) on days 1 and 15 and a fixed dose of FTD/TPI 35 mg/m2 twice daily (bid) on days 1–5 and 15–19 every 4 weeks were investigated in patients with refractory mCRC using a 3 + 3 design. Eligible patients had received prior oxaliplatin-based treatment that achieved a response or stable disease followed by confirmed disease progression at least 6 months before entering the study. Results Twelve patients were enrolled in the study. Three of six patients in the oxaliplatin 85 mg/m2 cohort had dose-limiting toxicities (DLTs) with treatment delays during the second cycle at ≥8 days due to grade ≥ 2 neutropenia or grade 2 AST/ALT increased. No DLTs were observed in the other cohorts. Grade ≥ 3 AEs were neutropenia (n = 3), thrombocytopenia (n = 1), anorexia (n = 1), and nausea (n = 1). There was no evidence of allergic reaction to oxaliplatin or severe peripheral sensory neuropathy. Conclusions A combination of FTD/TPI 35 mg/m2 bid on days 1–5 and 15–19 and oxaliplatin 85 mg/m2 on days 1 and 15 every 4 weeks could be a suitable regimen for the recommended dose of FTD/TPI plus oxaliplatin in patients with refractory mCRC.

Keywords

FTD/TPI Oxaliplatin Metastatic colorectal cancer DLT DNA damage 

Notes

Acknowledgments

We thank the participating patients, their family members, and all researchers involved in this study. We are grateful to Drs. Hiroyuki Uetake and Atsushi Sato for their support as the independent review committee, and to Yuki Horiike for collecting data. MS is the recipient of JSPS KAKENHI Grant Number 15 K06860. We also thank H. Nikki March, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

Compliance with ethical standards

Conflicts of interest

The authors declare no conflict of interest regarding the content discussed in the manuscript.

Ethical approval

This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the relevant Institutional Review Boards, the 1964 Helsinki declaration and its later amendments, and our institution’s ethical guidelines for clinical studies. The institutional review board at the Cancer Institute Hospital of the Japanese Foundation of Cancer Research approved the study protocol.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, Kuwata K, Hoff PM (2006) Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer 107:1383–1390CrossRefPubMedGoogle Scholar
  2. 2.
    Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372:1909–1919CrossRefPubMedGoogle Scholar
  3. 3.
    NCCN. Clinical practice guideline: Colon cancer. Ver. 4. 2018. Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed 27 Dec 2018
  4. 4.
    Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386–1422CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH et al (2018) Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol 29:44–70CrossRefPubMedGoogle Scholar
  6. 6.
    Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303–312CrossRefPubMedGoogle Scholar
  7. 7.
    de Gramont A, Buyse M, Abrahantes JC, Burzykowski T, Quinaux E, Cervantes A, Figer A, Lledo G, Flesch M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, Tournigand C (2007) Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol 25:3224–3229CrossRefPubMedGoogle Scholar
  8. 8.
    Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M et al (2015) Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Des Devel Ther 9:3099–3108CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Emura T, Murakami Y, Nakagawa F, Fukushima M, Kitazato K (2004) A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med 13:545–549PubMedGoogle Scholar
  10. 10.
    Temmink OH, Hoebe EK, van der Born K, Ackland SP, Fukushima M, Peters GJ (2007) Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells. Br J Cancer 96:231–240CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Calvo Ferrandiz A, Dahan L, Hollebecque A, Prager G, Andre T, Argiles Martinez G et al (2018) Safety run-in evaluation of the phase I trial of trifluridine/tipiracil (FTD/TPI) in combination with oxaliplatin and a monoclonal antibody (bevacizumab or nivolumab) in patients with metastatic colorectal cancer. Ann Oncol 29(suppl_8):viii150–viii204.  https://doi.org/10.1093/annonc/mdy281 CrossRefGoogle Scholar
  12. 12.
    Suzuki N, Nakagawa F, Nukatsuka M, Fukushima M (2011) Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks. Exp Ther Med 2:393–397CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Murgioni S, Rossini D, Marmorino F, Mennitto A, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R Jr, Barzi A, Yamaguchi T, Loupakis F, Lenz HJ (2017) Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. Ann Oncol 28:1015–1022CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Branzei D, Foiani M (2008) Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol 9:297–308CrossRefPubMedGoogle Scholar
  15. 15.
    Faivre S, Chan D, Salinas R, Woynarowska B, Woynarowski JM (2003) DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 66:225–237CrossRefPubMedGoogle Scholar
  16. 16.
    Nukatsuka M, Nakagawa F, Takechi T (2015) Efficacy of combination chemotherapy using a novel Oral chemotherapeutic agent, TAS-102, with Oxaliplatin on human colorectal and gastric Cancer xenografts. Anticancer Res 35:4605–4615PubMedGoogle Scholar
  17. 17.
    Doi T, Ohtsu A, Yoshino T, Boku N, Onozawa Y, Fukutomi A, Hironaka S, Koizumi W, Sasaki T (2012) Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumors. Br J Cancer 107:429–434CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Mitsukuni Suenaga
    • 1
    Email author
  • Takeru Wakatsuki
    • 1
  • Tetsuo Mashima
    • 2
  • Mariko Ogura
    • 1
  • Takashi Ichimura
    • 1
  • Eiji Shinozaki
    • 1
  • Izuma Nakayama
    • 1
  • Hiroki Osumi
    • 1
  • Yumiko Ota
    • 1
  • Daisuke Takahari
    • 1
  • Keisho Chin
    • 1
  • Hiroyuki Seimiya
    • 2
  • Kensei Yamaguchi
    • 1
  1. 1.Department of Gastroenterological ChemotherapyCancer Institute Hospital, Japanese Foundation for Cancer ResearchTokyoJapan
  2. 2.Division of Molecular Biotherapy, Cancer Chemotherapy CenterJapanese Foundation for Cancer ResearchTokyoJapan

Personalised recommendations